# Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

> **NCT04292769** · PHASE3 · UNKNOWN · sponsor: **Li Yu** · enrollment: 200 (estimated)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **DRUG:** Decitabine
- **BIOLOGICAL:** DC-CIK

## Key facts

- **NCT ID:** NCT04292769
- **Lead sponsor:** Li Yu
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-21
- **Primary completion:** 2023-01-20
- **Final completion:** 2023-01-20
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04292769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04292769, "Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04292769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*